BACKGROUND/AIM: Adenoid cystic carcinoma (AdCC) is a rare malignant tumor that primarily affects the salivary glands but can also occur in other organs. Low incidence and unpredictable clinical behavior make AdCC one of the most difficult head and neck tumors to treat. CASE REPORT: We present the case of a 54-year-old woman with AdCC localized at the base of the tongue, following radical surgical and oncological therapy. Due to advances in palliative oncological treatment, there is a more than five-year survival period before the progression of metastatic disease. Considering the rare occurrence of this disease, a literature search was also conducted, and therapy options are discussed. Ensuring a sufficient extent of the surgical procedure is still a challenge, and most specialists agree that subsequent postoperative radiotherapy reduces the risk of local recurrence. The effective dose of radiotherapy to the area of the primary tumor and lymph nodes is not clearly defined. CONCLUSION: The distinct biological behavior of AdCC results in varying sensitivity to chemotherapy or radiotherapy compared to treatments commonly used for head and neck squamous cell carcinomas. Treatment recommendations for these rarer tumors are based mainly on case reports and small clinical trials. The acquired therapeutic experience can contribute to prolonging the survival period of patients and improving their prognosis and quality of life.

Department of Oncology Charles University Faculty of Medicine and University Hospital Královské Vinohrady Prague Czech Republic

Department of Oncology Charles University Faculty of Medicine and University Hospital Královské Vinohrady Prague Czech Republic;

Department of Otorhinolaryngology Charles University Faculty of Medicine and University Hospital Královské Vinohrady Prague Czech Republic

Department of Pathology Charles University Faculty of Medicine and University Hospital Královské Vinohrady Prague Czech Republic

Department of Radiology and Nuclear Medicine Charles University Faculty of Medicine and University Hospital Královské Vinohrady Prague Czech Republic

Zobrazit více v PubMed

El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds.) WHO Classification of Head and Neck Tumors (4th edition) Lyon, France, International Agency for Research on Cancer. 2017

WHO Classification of Tumors Editorial Board Head and Neck Tumors. WHO classification of tumors series, 5th ed., vol. 9. Lyon, France, International Agency for Research on Cancer. 2022

Wenig Bruce M. Atlas of Head and Neck Pathology, Third edition. Philadelphia, PA, USA, Elsevier. 2016

Ammad U, Din M, Shaikh H. Adenoid Cystic Cancer. Treasure Island, FL, USA, StatPearls Publishing. 2024 PubMed

Ishikawa T, Tateda M, Oshima H, Sawada A, Oka N, Suzuki H, Hashimoto S. Metastasis of adenoid cystic carcinoma from a submandibular gland to the larynx. Auris Nasus Larynx. 2019;46(6):907–911. doi: 10.1016/j.anl.2018.11.001. PubMed DOI

Ouyang DQ, Liang LZ, Zheng GS, Ke ZF, Weng DS, Yang WF, Su YX, Liao GQ. Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern China: A 25-year retrospective study. Medicine (Baltimore) 2017;96(5):e5964. doi: 10.1097/MD.0000000000005964. PubMed DOI PMC

Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12(8):815–824. doi: 10.1016/S1470-2045(10)70245-X. PubMed DOI

Gandhi AK, Roy S, Biswas A, Bhasker S, Sharma A, Thakar A, Mohanti BK. Adenoid cystic carcinoma of head and neck: A single institutional analysis of 66 patients treated with multi-modality approach. Indian J Med Paediatr Oncol. 2015;36(3):166–171. doi: 10.4103/0971-5851.166729. PubMed DOI PMC

Tang X, Zhang C, Chen R, Zhou X, Zhang Y. Treatment of adenoid cystic carcinoma of the mobile tongue with anterolateral thigh flap reconstruction: A case report. Medicine (Baltimore) 2019;98(16):e15250. doi: 10.1097/MD.0000000000015250. PubMed DOI PMC

Sahara S, Herzog AE, Nör JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res. 2021;11(9):4092–4110. PubMed PMC

Ishida E, Ogawa T, Rokugo M, Ishikawa T, Wakamori S, Ohkoshi A, Usubuchi H, Higashi K, Ishii R, Nakanome A, Katori Y. Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up. Head Face Med. 2020;16(1):14. doi: 10.1186/s13005-020-00226-2. PubMed DOI PMC

Tchekmedyian V, Sherman EJ, Dunn L, Fetten JV, Michel LS, Kriplani A, Morris L, Ostrovnaya I, Katabi N, Haque S, Tran C, Azar J, Pfister DG, Ho AL. A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC) J Clin Oncol. 2019;37(15_suppl):6084–6084. doi: 10.1200/JCO.2019.37.15_suppl.6084. DOI

Luna-Ortiz K, Carmona-Luna T, Cano-Valdez AM, Mosqueda-Taylor A, Herrera-Gómez A, Villavicencio-Valencia V. Adenoid cystic carcinoma of the tongue—clinicopathological study and survival analysis. Head Neck Oncol. 2009;1:15. doi: 10.1186/1758-3284-1-15. PubMed DOI PMC

TNM klasifikace zhoubných novotvarů: česká verze 2017. 8.vyd. Praha: Ústav zdravotnických informací a statistiky České republiky. ISBN: 978-80-7472-173-1. 2017

Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A, Amini A. An updated review on head and neck cancer treatment with radiation therapy. Cancers (Basel) 2021;13(19):4912. doi: 10.3390/cancers13194912. PubMed DOI PMC

Dantas AN, Morais EF, Macedo RA, Tinôco JM, Morais Mde L. Clinicopathological characteristics and perineural invasion in adenoid cystic carcinoma: a systematic review. Braz J Otorhinolaryngol. 2015;81(3):329–335. doi: 10.1016/j.bjorl.2014.07.016. PubMed DOI PMC

Lukšić I, Suton P, Macan D, Dinjar K. Intraoral adenoid cystic carcinoma: is the presence of perineural invasion associated with the size of the primary tumour, local extension, surgical margins, distant metastases, and outcome. Br J Oral Maxillofac Surg. 2014;52(3):214–218. doi: 10.1016/j.bjoms.2013.11.009. PubMed DOI

Dudde F, Henkel KO, Barbarewicz F. Adenoid cystic carcinoma of the head and neck - treatment strategies of a highly malignant tumor with variable localizations. Oncoscience. 2023;10:27–29. doi: 10.18632/oncoscience.581. PubMed DOI PMC

Coca-Pelaz A, Rodrigo JP, Bradley PJ, Vander Poorten V, Triantafyllou A, Hunt JL, Strojan P, Rinaldo A, Haigentz M Jr, Takes RP, Mondin V, Teymoortash A, Thompson LD, Ferlito A. Adenoid cystic carcinoma of the head and neck – An update. Oral Oncol. 2015;51(7):652–661. doi: 10.1016/j.oraloncology.2015.04.005. PubMed DOI

Fang Y, Peng Z, Wang Y, Gao K, Liu Y, Fan R, Zhang H, Xie Z, Jiang W. Current opinions on diagnosis and treatment of adenoid cystic carcinoma. Oral Oncol. 2022;130:105945. doi: 10.1016/j.oraloncology.2022.105945. PubMed DOI

Gao RW, Routman DM, Harmsen WS, Ebrahimi S, Foote RL, Ma DJ, Neben-Wittich M, McGee LA, Patel SH, Moore EJ, Choby GW, Tasche KK, Price KA, Gamez ME, Lester SC. Adenoid cystic carcinoma of the head and neck: Patterns of recurrence and implications for intensity-modulated radiotherapy. Head Neck. 2023;45(1):187–196. doi: 10.1002/hed.27223. PubMed DOI

Krucoff KB, Shammas RL, Stoecker M, Tolnitch LA. Rare breast metastasis from adenoid cystic carcinoma of the submandibular gland. BMJ Case Rep. 2018;2018:bcr2017223345. doi: 10.1136/bcr-2017-223345. PubMed DOI PMC

Chen Y, Zheng ZQ, Chen FP, Yan JY, Huang XD, Li F, Sun Y, Zhou GQ. Role of postoperative radiotherapy in nonmetastatic head and neck adenoid cystic carcinoma. J Natl Compr Canc Netw. 2020;18(11):1476–1484. doi: 10.6004/jnccn.2020.7593. PubMed DOI

Rui X, Huang Z, Chen R, Chen Y, Wang Y, Huang Z. RPS3 promotes the metastasis and cisplatin resistance of adenoid cystic carcinoma. Front Oncol. 2022;12:804439. doi: 10.3389/fonc.2022.804439. PubMed DOI PMC

Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY, Sunwoo JB. CD44+ cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clin Cancer Res. 2016;22(14):3571–3581. doi: 10.1158/1078-0432.CCR-15-2665. PubMed DOI PMC

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B. Pembrolizumab for the treatment of advanced salivary gland carcinoma: Findings of the Phase 1b KEYNOTE-028 study. Am J Clin Oncol. 2018;41(11):1083–1088. doi: 10.1097/COC.0000000000000429. PubMed DOI PMC